CD207 and Langerhans cell histiocytosis: In a cohort containing 100 pediatric patients (age range 0–9.3 years), the expression of BRAFV600E in CD207+ cells in LCH lesions did not correlate with clinical risk groups, risk of central nervous system involvement, or diabetes insipidus state but was associated with a higher risk of recurrence [6, 62].